Literature DB >> 32149958

The Influence of Screening, Misclassification, and Reporting Biases on Reported Chlamydia Case Rates Among Young Women in the United States, 2000 Through 2017.

Emily R Learner1, Kimberly A Powers2, Elizabeth A Torrone1, Brian W Pence2, Jason P Fine3, William C Miller4.   

Abstract

BACKGROUND: National chlamydia case rate trends are difficult to interpret because of biases from partial screening coverage, imperfect diagnostic tests, and underreporting. We examined the extent to which these time-varying biases could influence reported annual chlamydia case rates.
METHODS: Annual reported case rates among women aged 15 through 24 years from 2000 through 2017 were obtained from the Centers for Disease Control and Prevention's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention AtlasPlus tool. Estimates of reporting completeness, diagnostic test sensitivity and specificity, and screening coverage were derived from literature review and expert opinion. We adjusted annual reported case rates for incomplete reporting, imperfect diagnostic tests, and partial screening coverage through a series of corrections, and calculated annual adjusted case rates of correctly diagnosed chlamydia.
RESULTS: Adjusted chlamydia case rates among young women were higher than reported case rates throughout the study period. Reported case rates increased over the study period, but adjusted rates declined from 12,900 to 7900 cases per 100,000 person-years between 2000 and 2007. After 2007, adjusted case rates declined to 7500 cases per 100,000 person-years in 2017. Bias from partial screening coverage had a larger impact on case rate magnitude and trend shape than bias from imperfect diagnostic tests or underreporting.
CONCLUSIONS: Reported chlamydia case rates may be substantially lower than true chlamydia case rates because of incomplete reporting, imperfect diagnostic tests, and partial screening coverage. Because the magnitude of these biases has declined over time, the differences between reported and adjusted case rates have narrowed, revealing a sharp decline in adjusted case rates even as reported case rates have risen. The decline in adjusted case rates suggests that the rise in reported case rates should not be interpreted strictly as increasing chlamydia incidence, as the observed rise can be explained by improvements in screening coverage, diagnostic tests, and reporting.

Entities:  

Mesh:

Year:  2020        PMID: 32149958      PMCID: PMC8711091          DOI: 10.1097/OLQ.0000000000001157

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  18 in total

Review 1.  The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review.

Authors:  Emma J Watson; Allan Templeton; Ian Russell; Jorma Paavonen; Per-Anders Mardh; Angelika Stary; Babil Stray Pederson
Journal:  J Med Microbiol       Date:  2002-12       Impact factor: 2.472

2.  The Significant Impact of Different Insurance Enrollment Criteria on the HEDIS Chlamydia Screening Measure for Young Women Enrolled in Medicaid and Commercial Insurance Plans.

Authors:  Chirag G Patel; Guoyu Tao
Journal:  Sex Transm Dis       Date:  2015-10       Impact factor: 2.830

3.  Estimating chlamydia screening coverage: a comparison of self-report and health care effectiveness data and information set measures.

Authors:  Christine M Khosropour; Jennifer M Broad; Delia Scholes; Jacquelyn Saint-Johnson; Lisa E Manhart; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2014-11       Impact factor: 2.830

4.  Uptake of regular chlamydia testing by U.S. women: a longitudinal study.

Authors:  Janneke C M Heijne; Guoyu Tao; Charlotte K Kent; Nicola Low
Journal:  Am J Prev Med       Date:  2010-09       Impact factor: 5.043

5.  Estimating Chlamydia screening rates by using reported sexually transmitted disease tests for sexually active women aged 16 to 25 years in the United States.

Authors:  Guoyu Tao; Lin H Tian; Thomas A Peterman
Journal:  Sex Transm Dis       Date:  2007-03       Impact factor: 2.830

6.  The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection.

Authors:  Robert C Brunham; Babak Pourbohloul; Sunny Mak; Rick White; Michael L Rekart
Journal:  J Infect Dis       Date:  2005-10-10       Impact factor: 5.226

7.  Chlamydia screening of young sexually active, Medicaid-insured women by race and ethnicity, 2002-2005.

Authors:  Lauren Christiansen-Lindquist; Guoyu Tao; Karen Hoover; Robbie Frank; Charlotte Kent
Journal:  Sex Transm Dis       Date:  2009-10       Impact factor: 2.830

Review 8.  Screening for gonorrhea and Chlamydia: a systematic review for the U.S. Preventive Services Task Force.

Authors:  Bernadette Zakher; Amy G Cantor; Miranda Pappas; Monica Daeges; Heidi D Nelson
Journal:  Ann Intern Med       Date:  2014-12-16       Impact factor: 25.391

9.  Uptake and population-level impact of expedited partner therapy (EPT) on Chlamydia trachomatis and Neisseria gonorrhoeae: the Washington State community-level randomized trial of EPT.

Authors:  Matthew R Golden; Roxanne P Kerani; Mark Stenger; James P Hughes; Mark Aubin; Cheryl Malinski; King K Holmes
Journal:  PLoS Med       Date:  2015-01-15       Impact factor: 11.069

10.  Estimating Local Chlamydia Incidence and Prevalence Using Surveillance Data.

Authors:  Joanna Lewis; Peter J White
Journal:  Epidemiology       Date:  2017-07       Impact factor: 4.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.